Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: Thiazolidinediones are partial PPARγ agonists  by Chana, Ravinder S. et al.
Kidney International, Vol. 65 (2004), pp. 2081–2090
Differential effects of peroxisome proliferator activated
receptor-c (PPARc) ligands in proximal tubular cells:
Thiazolidinediones are partial PPARc agonists
RAVINDER S. CHANA, ANDREW J. LEWINGTON, and NIGEL J. BRUNSKILL
Department of Cell Physiology and Pharmacology, and Department of Nephrology, University of Leicester, Faculty of Medicine
and Biological Sciences, Leicester, England, United Kingdom
Differential effects of peroxisome proliferator activated
receptor-c (PPARc) ligands in proximal tubular cells: Thiazo-
lidinediones are partial PPARc agonists.
Background. Peroxisome proliferator activated receptors
(PPARs) are ligand-activated transcription factors with multi-
ple effects on target cell function. PPARc activity is regulated by
extracellular signal-regulated protein kinase (ERK), mitogen-
activated protein (MAP) kinase, and PPARc ligands have vary-
ing effects on activity of ERK. Different PPARc ligands have
been shown to have both protective and detrimental effects in
the kidney. Since transcriptional activation by different PPAR
agonists is ligand- and depot-specific PPARc, we have exam-
ined the effects of different agonists on PPAR activity in the
proximal tubule.
Methods. Opossum kidney cells were used in all experi-
ments, transiently transfected with a PPAR response element lu-
ciferase reporter and subject to stimulation with various PPAR
ligands. The role of ERK and phosphorylation in PPARc acti-
vation were studied, as were the effects of PPAR agonists on
ERK activation and cell proliferation.
Results. Transcriptional activity of PPAR was not stimu-
lated by PPARa agonists, and only very modestly stimulated
by a PPARb agonist. The PPARc agonists 15-deoxy-12,14-
prostaglandin J2 (15d-PGJ2), ciglitazone, and troglitazone
stimulated significant transcriptional activation and phospho-
rylation of PPARc. These effects were more marked with 15d-
PGJ2. Thiazolidinediones attenuated 15d-PGJ2 evoked PPARc
activation and phosphorylation. ERK activity positively regu-
lated PPAR activation. Only 15d-PGJ2 stimulated ERK activity
and cell proliferation, and these effects were also inhibited by
thiazolidinediones.
Conclusion. PPARc agonists exert differential effects in
proximal tubule cells with thiazolidinediones behaving as par-
tial agonists.
Key words: proximal tubule, PPAR, thiazolidinedione, ciglitazone,
troglitazone prostaglandin, partial agonist, MAP kinase, phosphory-
lation.
Received for publication June 4, 2003
and in revised form November 26, 2003, and December 22, 2003
Accepted for publication January 15, 2004
C© 2004 by the International Society of Nephrology
The peroxisome proliferator activated receptors
(PPARs), PPARa, -b/d, and -c, are ligand-activated tran-
scription factors belonging to the nuclear hormone su-
perfamily that also includes the retinoic acid and thy-
roid hormone receptors. Upon ligand binding, PPARs
form heterodimers with one of the three retinoid X re-
ceptor proteins which then bind to PPAR response el-
ements (PPRE) within the promoter regions of target
genes. They have been shown to regulate diverse cell
functions, including adipocyte differentiation, control of
inflammation, fatty acid metabolism, cell cycle control,
and the development of atherosclerosis [1–3]. A variety
of endogenous and exogenous ligands for PPARs have
been identified [4]. PPARa is the target for the hypolipi-
demic fibrate drugs, and PPARc the target for the antidia-
betic thiazolidinediones. Most fatty acids can also activate
PPARs. A number of eicosanoids have also been shown
to activate PPARs (e.g., 5, 8, 11, 14 eicosatetraynoic acid
(ETYA) for PPARa, and 15-deoxy-12,14-prostaglandin
J2 (15d-PGJ2) for PPARc.
Although all three PPAR subtypes have been iden-
tified in mammalian kidneys [5–7], their role in regu-
lating renal (patho)physiology is only just beginning to
be unraveled. The most widely investigated subtype in
the context of kidney function is PPARc, and some ani-
mal studies have suggested a protective effect of thiazo-
lidinediones in both diabetic and nondiabetic models of
renal disease [8, 9]. However, the response of glomeru-
lar cells to PPARc activation may be agonist dependent,
with some agonists potentially augmenting detrimental
inflammatory responses in glomerulonephritis [10]. In
vitro, PPARc agonists suppress secretion of type I col-
lagen by mesangial cells [11] and may protect mesangial
cells from lipid-induced injury [12]. In contrast, stimula-
tion of PPARc by fatty acids presented to proximal tubu-
lar cells bound to albumin results in profound apoptosis
[13].
Transcriptional activation by different PPAR agonists
is ligand- and depot-specific. Different thiazolidinediones
2081
2082 Chana et al: Thiazolidiendiones are partial PPARc agonists
acting through PPARc may induce differential gene tran-
scription, and the effects of PPARc agonists are likely
to differ between cell types [14–18]. Thus the effects of
PPAR activation in kidney cells are likely to be complex
and context specific, and it remains unclear under what
circumstances PPAR activation in the kidney may be ben-
eficial or deleterious.
Mitogen-activated protein (MAP) kinases are key
mediators involved in the intracellular network of in-
teracting proteins that transduce extracellular stimuli to
intracellular responses. Extracellular signal-regulated ki-
nases (ERK) were the first reported and are the best
described members of the MAP kinases. The two ERK
isoforms, ERK1 (or p44 MAP kinase) and ERK2 (or p42
MAP kinase), are serine/threonine kinases that regulate
the expression of many genes via the phosphorylation of
numerous families of transcription factors [19, 20]. Activ-
ity of ERK has been shown to have a central role in the
development of both glomerular and tubular dysfunction
[21, 22, 23].
PPARc is a phosphoprotein whose activity is regu-
lated by phosphorylation in addition to ligand binding.
The MAP kinases, particularly ERK, may mediate this
phosphorylation, but data regarding the effects of ERK-
induced PPARc phosphorylation on PPARc activation
are conflicting. Hu et al [24] reported that ERK me-
diated phosphorylation of PPARc resulted in reduced
transcriptional activity and inhibition of adipocyte differ-
entiation. Conversely Zhang et al [25] demonstrated the
opposite effect of ERK on PPARc transcriptional activity
in transiently transfected Chinese hamster ovary (CHO)
cells [25]. Subsequently, the balance of evidence has sup-
ported an inhibitory role for ERK in the regulation of
PPARc transcriptional activity [26–28]. Similar tension
exists in the literature regarding the ability of PPARc lig-
ands to activate ERK. In mesangial cells 15d-PGJ2, but
not the thiazolidinedione ciglitazone, is able to activate
ERK independently of PPARc [29]. Human T cells have
also been shown to respond in a similar manner to 15d-
PGJ2 [30], whereas in astrocytes and preadipocytes ERK
is activated by both 15d-PGJ2 and ciglitazone [31].
Although PPAR agonists have shown promise in the
treatment of kidney disease, their role in the modula-
tion of renal pathology requires further clarification. In
particular studies of progression of nephropathy in dia-
betic patients treated with thiazoidinediones are not yet
available, but will be of considerable interest given the
observed pleiotropic effects of these agents on renal cell
function. An intriguing question is whether a PPARc
agonist with beneficial effects on proximal tubular cell
function, such as a thiazolidinedione, may be used to
antagonize the potentially deleterious effects of other
PPARc agonists such as albumin bound fatty acids [13].
We have therefore examined the effects of various PPAR
ligands to activate PPAR in opossum kidney proximal
tubular cells, and particularly studied the differences and
similarities in signaling between the thiazolidinediones
and 15d-PGJ2 in these cells.
METHODS
Reagents and cell culture
Opossum kidney cells were originally obtained from
J Caverzasio and grown in Dulbecco’s modified Ea-
gle’s medium/F-12 (DMEM/F-12) mix supplemented
with 10% fetal calf serum (FCS), 2 mmol/L L-glutamine,
100 U/mL penicillin, and 0.1 mg/mL streptomycin under
standard culture conditions.
General laboratory chemicals were obtained from
Sigma (Poole, UK) and were of the highest grade
available. The PPAR agonists 15d-PGJ2, 5, 8, 11, 14-
eicosatetraynoic acid (ETYA), 4-chloro-6-(2,3-xylindo)-
2-pyrimidinylthioacetic acid (WY-14643), ciglitazone,
and troglitazone were obtained from Biomol Re-
search Laboratories (Plymouth Meeting, PA, USA).
The PPARb agonist carbaprostacyclin was obtained
from Alexis Corporation (Nottingham, England). 9 cis
retinoic acid was obtained from Sigma as were all
general laboratory chemicals that were of the highest
grade available. [32P]-orthophosphate was obtained from
Amersham (Amersham Pharmacia Biotech, Little Chal-
font, England).
The constitutively active MAP kinase kinase (MEK1)
mutant expressing plasmid, pFC-MEK1 (pMEK1-CA),
was obtained from Stratagene (La Jolla, CA, USA), the
kinase dead mutant of MEK1 in pCMV5 (pMEK1-KD)
was provided by Dr Jonathan Blank (Leicester, England).
The reporter plasmid pPPRE-TK-Luc was kindly pro-
vided by Dr M. Lazar (Philadelphia, PA, USA). Fugene 6
transfection reagent was purchased from Roche Diagnos-
tics (Lewes, England). Luciferase assays were performed
using LucLite kit (Packard, Pangbourne, England). b-
galactosidase assay kits were obtained from Promega
(Madison, WI, USA). Antibodies against active phos-
phorylated ERK (pERK) and total ERK were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
supplied by Insight Biotechnology (London, England).
Antimouse horseradish peroxidase (HRP)-conjugated
secondary antibody and antirabbit HRP-conjugated sec-
ondary antibody were purchased from Sigma.
Transient transfection and luciferase reporter assays
Opossum kidney cells were transfected with pPPRE-
TK-Luc, pMEK1-CA, pMEK1-KD, and pSVb-Gal
using Fugene-6 according to the manufacturer’s instruc-
tions. Briefly, 25,000 cells per well plated in 24-well plates
were grown overnight to approximately 50% confluency.
Cells were then transfected with various combinations
of pPPRE-TK-luc, pMEK1-CA, and pMEK1-KD, to-
gether with pSVbgal to control for transfection efficiency,
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in complete DMEM/F-12 medium for 24 hours. During
transfection the DNA ratio was kept constant in all exper-
iments such that 0.25 lg of each plasmid DNA was used
per well and the quantity of Fugene-6 varied according
to the quantity of plasmid DNA.
After transfection, the cells were growth arrested in
serum-free DMEM/F-12 medium for 24 hours. Cells were
then stimulated in this medium containing the PPAR ag-
onists 15d-PGJ2 (0 to 20 lmol/L), ciglitazone or troglita-
zone (0 to 20 lmol/L), ETYA (0 to 20 lmol/L), WY14643
(0 to 20 lmol/L), carbaprostacyclin (0 to 20 lmol/L), 9-cis
retinoic acid (0 to 20 lmol/L), and vehicle [either 0.1%
dimethyl sulfoxide (DMSO), or 0.1% ethanol]. After
24 hours, the media was removed and cells lysed in
a buffer consisting of 500 mmol/L HEPES, 1 mmol/L
CaCl2, 1 mmol/L MgC2 containing 2% Triton N101, pH
7.8. Cells were lysed for 10 minutes, 100 lL aliquots
of lysate were assayed for luciferase, the remainder be-
ing used for b-galactosidase assay. Luciferase activity
was measured using a Lumicount luminometer (Packard,
Pangbourne, England) and b-galactosidase using a Spec-
trocount spectrophotometer (Packard).
Assessment of cell viability and proliferation
Cell viablilty in response to PPAR and other agonists
was determined by methylthiazoletetrazolium (MTT) as-
say. Opossum kidney cells, prestimulated for 24 hours
with varying concentrations of agonists, were incubated
with 50 lL of 2 mg/mL MTT solution for 1 hour and solu-
bilized in DMSO. The formation of the formazan product
was measured with a spectrophotometer set to record ab-
sorbance at 540 nm.
Cell proliferation was assessed [3H] thymidine assay as
previously described [32]. Briefly, cells, growing in 96-well
plates, were exposed to varying concentrations of PPAR
agonists. Incorporation of [3H] thymidine (3.6 lCi/mL
culture medium) into nuclear DNA was terminated af-
ter 3 hours by washing with phosphate-buffered saline
(PBS). The cells were fixed at 4◦C by first adding 50%
methanol/10% glacial acetic acid for 30 minutes and then
trichloroacetic acid (10%) for 10 minutes, before being
solubilized overnight in 100 mmol/l sodium hydroxide so-
lution containing 1% sodium dodecyl sulfate (SDS). Ra-
dioactivity was counted using a beta scintillation counter.
[32P]-orthophosphate metabolic labeling of cells
and immunoprecipitation with anti-PPARc antibody
Opossum kidney cells were metabolically labeled
with [32P]-orthophosphate as previously described [32].
Briefly, cells grown to confluence in 6-well plates
were growth arrested in serum-free medium overnight,
washed, and then treated with serum-free, phosphate-
free DMEM/F-12 medium containing either 200 lCi/mL
[32P]-orthophosphate alone or with this medium con-
taining PGJ2 (5 lmol/L) and ciglitazone (5 lmol/L)
for 4 hours at 37◦C. After stimulation, the cells were
washed twice with ice cold PBS, pH 7.4, and lysed in ly-
sis buffer consisting of 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS, 200 lmol/L phenylmethylsul-
fonylfluoride (PMSF), and 200 lmol/L sodium vanadate
prepared in PBS, pH 7.4. Lysates were collected after
20 minutes incubation and then precleared with the ad-
dition of protein A-sepharose for 30 minutes at 4◦C. The
supernatants were then incubated overnight with 10 lL
aliquots of anti-PPARc antibody at 4◦C. The resulting im-
mune complexes were immunoprecipitated with protein
A-sepharose, washed three times with cold lysis buffer
and prepared for SDS-polyacrylamide gel electrophore-
sis (PAGE) by the addition of 30 lL of Laemmli buffer
containing 60 mmol/L Tris, pH 6.8, 10% glycerol, 2%
SDS, 100 mmol/L dithiothreitol (DTT), and 0.01% bro-
mophenol blue. The immunoprecipitated proteins were
subjected to 10% SDS-PAGE and radiolabeled proteins
detected by autoradiography. For densitometric analysis,
bands on exposed x ray film derived from immunoprecip-
itation experiments were scanned and quantified using
Scion Image version 4.0.2.
Assessment of MAP kinase activation
The MAP kinase activation in opossum kidney cells in
response to PPARc agonists was examined by Western
blot analysis. Cells grown to 50% confluency in 24-well
plates were growth arrested in serum-free medium for
24 hours and then treated with PGJ2 (5 lmol/L), cigli-
tazone (5 lmol/L), troglitazone (5 lmol/L), or medium
alone containing vehicle. After incubation at varying time
points, cells were washed and lysed in Laemmli buffer as
described above. After PAGE and Western blotting of
lysate proteins, pERK was detected using a monoclonal
anti-pERK antibody (1:1000) and secondary HPR-linked
antimouse IgG antibody (1:5000). Total ERK was de-
tected with polyclonal anti-ERK antibody (1:1000) and
secondary HRP-linked antirabbit IgG antibody (1:5000).
Bound antibodies were visualized using enhanced chemi-
luminescence (ECL) (Amersham Pharmacia Biotech).
RESULTS
Our first aim was to establish a repertoire of responses
in opossum kidney cells to stimulation with a variety
of potential agents likely to influence PPAR activation
via PPRE (Fig. 1). Treatment of opossum kidney cells
with the PPARa ligands WY14643 and ETYA caused
no significant stimulation of PPRE-driven luciferase ex-
pression. Conversely, treatment with the PPARc lig-
ands 15-dPGJ2 and the thiazolidinediones ciglitazone and
troglitazone stimulated significant luciferase expression
(187.9% ± 34%, 137.1% ± 10%, 133.9% ± 11.6% of
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Fig. 1. Activation of peroxisome proliferator activated receptors (PPAR) response elements (PPRE) by various PPAR ligands in opossum
kidney cells. Opossum kidney cells were transiently transfected with pPPRE-TK-luc and then stimulated with increasing concentrations of PPARc
ligands 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2) (A) and ciglitazone () or troglitazone ( ) (B), PPARa ligands WY14643 (C), 5, 8, 11, 14
eicosatetraynoic acid (ETYA) (D), PPARb ligand carbaprostacyclin (E), and retinoic acid receptor ligand 9-cisRA (F). All luciferase values are
given as a percentage of nonstimulated controls. Values are expressed as means ± SEM. Each condition was measured in triplicate in three to six
experiments.
control, respectively, at 5 lmol/L). The PPARb agonist
carbaprostacyclin induced a very modest increase in lu-
ciferase activity (125% ± 7.2% of control at 5 lmol/L),
whereas the ligand of the retinoic acid receptor 9-cis
retinoic acid elicited a robust stimulation of luciferase
activity (197.2% ± 16.7% of control at 5 lmol/L).
We went on to examine the effect on PPRE-driven
luciferase expression of combining different PPARc ag-
onists and/or 9-cis retinoic acid together (Fig. 2). The
combination of 15d-PGJ2 and 9-cis retinoic acid re-
sulted in significant augmentation of PPRE activation
over and above that observed with either agent alone.
Conversely, when 9-cis retinoic acid was combined with
ciglitazone, no enhancement was observed; indeed the
level of luciferase expression was lower than that ex-
pected in the setting of 9-cis retinoic acid stimulation
alone (Fig. 2A). Furthermore, when pPPRE transfected
cells were treated with 5 lmol/L 15d-PGJ2 combined
with varying concentrations of ciglitazone or troglita-
zone (Fig. 2B), the luciferase expression expected with 5
lmol/L 15d-PGJ2 alone was reduced in a dose-dependent
manner.
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Fig. 2. Effect on peroxisome proliferator activated receptors (PPAR)
response elements (PPRE) activation in opossum kidney cells of com-
bining PPAR and retinoic acid receptor ligands. (A) Opossum kid-
ney cells were transiently transfected with pPPRE-TK-luc and then
stimulated with either 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2)or
ciglitazone alone and with varying concentrations of retinoic acid. Lu-
ciferase values are given as a percentage of nonstimulated controls. (B)
Opossum kidney cells were transiently transfected with pPPRE-TK-luc
and then stimulated with 5 lmol/L 15d-PGJ2 and varying concentra-
tions of ciglitazone (, unbroken line) or troglitazone (, broken line).
Luciferase values are given as a percentage of the maximal response
seen with 5 lmol/L 15d-PGJ2 alone. Values are expressed as means ±
SEM. Each condition was measured in triplicate in four experiments.
All of the agonists used, except carbaprostacyclin and
WY14643, demonstrated a reduction in luciferase activ-
ity at concentrations ≥10 lmol/L. Assessment of cell via-
bility under these conditions (Fig. 3A) demonstrated that
for all the agents exhibiting reduced luciferase expression
impairment of cell viability developed at 10 lmol/L con-
centrations, very marked impairment of viability was ap-
parent at higher concentrations. Combination of various
concentrations of troglitazone with 5 lmol/L 15d-PGJ2
resulted in no greater toxicity than with 15d-PGJ2 alone.
The addition of increasing concentrations of ciglitazone
to 15d-PGJ2 revealed a modest trend toward increasing
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Fig. 3. Toxicity of peroxisome proliferator activated receptors (PPAR)
ligands in opossum kidney cells. (A) Opossum kidney cells were treated
with increasing concentrations of various PPAR ligands and the po-
tential toxic effects on cells determined by methylthiazoletetrazolium
(MTT) assay. Values represent mean ± SEM, and are normalized to
that observed under nonligand-treated conditions given as 100%. Each
condition was performed in triplicate on three occasions. (B) Opossum
kidney cells were treated with 5 lmol/L 15-deoxy-12,14-prostaglandin
J2 (15d-PGJ2) alone () or together with indicated concentrations of
ciglitazone () or troglitazone ( ). Potentially toxic effects on cells were
determined by MTT assay performed in triplicate on three occasions.
Values represent mean ± SEM, and are normalized to that observed in
cells treated with 15d-PGJ2 alone given as 100%.
toxicity. Therefore in the majority of experiments 15d-
PGJ2 was combined with concentrations of thiazolidine-
dione less than 5 lmol/L.
We next examined the phosphorylation state of PPARc
under basal conditions and after stimulation by the
PPARc agonists 15d-PGJ2 and ciglitazone (Fig. 4). A
representative autoradiograph showing phospho-PPARc
is depicted in Figure 4A, with a histogram represent-
ing quantification of bands in Figure 4B. Low levels of
PPARc phosphorylation were observed under control
conditions. Exposure of cells to 15d-PGJ2 resulted in
an approximate 2.5-fold enhancement of PPARc phos-
phorylation, whereas ciglitazone stimulated a lesser de-
gree of phosphorylation. Interestingly, the combination
2086 Chana et al: Thiazolidiendiones are partial PPARc agonists
A
0
1
2
3
Fo
ld
 c
ha
ng
e 
in
 p
ho
sp
ho
ry
la
tio
n
co
m
pa
re
d 
to
 c
on
tro
l
Control Ciglit Ciglit
+
PGJ2
PGJ2
B
Fig. 4. Phosphorylation of peroxisome proliferator activated recep-
tors (PPARc) in [32P]-orthophosphate–labeled opossum kidney cells.
Opossum kidney cells were labeled with [32P]-orthophosphate and stim-
ulated with either 5 lmol/L 15-deoxy-12,14-prostaglandin J2 (15d-
PGJ2), 5lmol/L ciglitazone, or both PPARc ligands in combination.
PPARc was then immunoprecipitated and its phosphorylation state ex-
amined by polyacrylamide gel electrophoresis (PAGE) and autoradiog-
raphy. (A) A representative utoradiograph of phosphorylated PPARc.
(B) A histogram demonstrates denistometric quantification of phospho-
rylated bands depicted above. The level of phosphorylation observed
under control, nonstimulated, noninhibitor-treated conditions has been
arbitrarily assigned a value of 1. All other values have been normalized
to this. The experimental condition relevant to each band of the au-
toradiograph is indicated below the respective histogram bar. The data
depicted are representative of at least three identical experiments.
of ciglitazone and 15d-PGJ2 was not associated with aug-
mentation of the PPARc phosphorylation observed with
15d-PGJ2 alone, but rather a reduction.
To study the influence of ERK on 15d-PGJ2 and
ciglitazone-stimulated luciferase activity, we transfected
opossum kidney cells with either pMEK1-CA or pMEK1-
KD together with pPPRE-TK-luc prior to agonist stimu-
lation (Fig. 5). In some experiments cells underwent mock
transfection with irrelevant plasmid DNA as controls, and
in these cells the pattern of luciferase expression in re-
sponse to 15d-PGJ2 and ciglitazone was as in previous
experiments (Fig. 1). Transfection of cells with constitu-
tively active MEK1 resulted in enhanced PPRE activa-
tion in unstimulated cells. Agonist treatment with either
15d-PGJ2 or ciglitazone stimulated no further significant
increase in PPRE activation in pMEK1-CA transfected
cells. Conversely, expression of kinase dead MEK1 inhib-
ited basal PPRE activation, and that stimulated by both
15d-PGJ2 and ciglitazone.
In order to determine the ability of PPARc agonists to
stimulate ERK we used Western blotting of opossum kid-
ney cell lysates for pERK (Fig. 6). In initial experiments
we sometimes observed an early (5 minutes) apparent
stimulation of ERK by 5 lmol/L ciglitazone. However, a
similar response was also occasionally seen following sim-
ple media change in some experiments, and we therefore
concluded that no significant activation of ERK occurred
in response to this agent. No stimulation of ERK by trogli-
tazone was observed (data not shown). In contrast, ex-
posure of opossum kidney cells to 5 lmol/L 15d-PGJ2
resulted in significant ERK activation after 30 minutes,
persisting for at least 4 hours. No such pattern of activa-
tion was ever observed following media change alone, and
we therefore concluded that 15d-PGJ2 was able to stimu-
late ERK in opossum kidney cells. Very significantly both
ciglitazone and troglitazone dose dependently inhibited
15d-PGJ2-evoked ERK activation (Fig. 7).
Proliferation was used as an index of the functional ef-
fects of PPARc agonists in opossum kidney cells (Fig. 8).
15d-PGJ2 stimulated a robust dose-dependent increase
in opossum kidney cell proliferation, whereas the thiazo-
lidinediones ciglitazone and troglitazone had an opposite
effect (Fig. 8A). When both 5 lmol/L 15d-PGJ2 and vary-
ing concentrations of thiazolidinediones were applied to
opossum kidney cells, a dose-dependent inhibitory effect
of thiazolidinediones on 15d-PGJ2-stimulated prolifera-
tion was seen (Fig. 8B).
DISCUSSION
Various studies have examined the localization of
PPAR subtypes in the kidney [5–7], but their physiologic
functions in this organ and potential roles in kidney dis-
ease are not well understood. For PPARc both protective
and detrimental influences on kidney cell behavior have
been described [8–13]. For instance, we demonstrated in
primary human proximal tubular cells that activation of
PPARc by albumin-bound fatty acids and 15d-PGJ2 re-
sulted in apoptosis [13]. We postulated that this effect
might be responsible in part for tubular atrophy observed
in proteinuric renal disease. Additionally, we suggested
that other PPARc ligands could possess the potential to
prevent PPARc-mediated fatty acid–induced proximal
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Fig. 5. Activation of peroxisome prolifera-
tor activated receptors (PPAR) response el-
ements (PPRE) by PPARc ligands in cells
transfected with kinase dead or constitutively
active mitogen-activated protein (MAP) ki-
nase kinase (MEK1). Opossum kidney cells
were transiently transfected with pPPRE-
TK-luc together with either pMEK1-CA or
pMEK1-KD, or mock transfected with irrele-
vant DNA. Luciferase activity was measured
in non-stimulated cells or cells stimulated with
the indicated PPARc ligands. Luciferase val-
ues are given as a percentage of that seen
in mock transfected, nonstimulated controls.
Values are expressed as means ± SEM. Each
condition was measured in triplicate in four
experiments.
tubular toxicity [13]. Despite the previous observations
that PPARa was the most highly expressed subtype in
the kidney proximal tubule [5–7] we demonstrated that
PPARc agonists rather than PPARa agonists elicited the
greatest activation of PPRE in human proximal tubu-
lar cells [13]. We now report similar findings in opossum
kidney proximal tubular cells. In the current study only
PPARc ligands stimulate appreciable PPRE activity in
opossum kidney cells. In fact, PPARa ligands fail to acti-
vate PPRE, and PPARb ligand-stimulated PPRE activity
is trivial. With regard to PPARc ligands it is significant
that 15d-PGJ2 exhibited a more potent PPRE stimula-
tory effect than two different thiazolidinediones, ciglita-
zone and troglitazone, in all our experiments, such that
despite increasing concentrations thiazolidinediones only
partially activate PPRE.
We went on to examine the differential effects of thi-
azolidinediones and 15d-PGJ2 on signaling pathways,
and cell functional events known to be associated with
PPARc mediated activities. Despite both being high-
affinity ligands for, and agonists of, PPARc [33, 34], im-
portant differences between the activities of 15d-PGJ2
and thiazolidinediones in opossum kidney cells are re-
vealed in this study. Whereas 15d-PGJ2 and 9-cis retinoic
acid exert a synergistic effect on PPRE activation, no
such synergy is observed between 9-cis retinoic and cigli-
tazone. Both ciglitazone and troglitazone reverse 15d-
PGJ2–induced PPRE activation, resulting in levels of
PPRE activation similar to those observed with the
thiazolidinedione alone. Ciglitazone induces less phos-
phorylation of PPARc than 15d-PGJ2, and inhibits 15d-
PGJ2–stimulated phosphorylation PPARc. Activation of
ERK by 15d-PGJ2 is also inhibited by both thiazo-
lidinediones, as is 15d-PGJ2–stimulated proliferation of
opossum kidney cells, although ciglitazone displays the
greatest potency in this respect.
Other interesting points emerge from the current study
in relation to the stimulation of ERK by PPARc lig-
ands and its role in activation of PPARc. In many pub-
lished studies activation of ERK, and ERK-mediated
phosphorylation of PPARc is associated with a reduc-
tion in its transcriptional activity [24, 26–28, 35, 36]. How-
ever, the data from the current experiments using mutant
MEK1, performed in a physiologically relevant cell line
expressing only endogenous PPARc rather than over-
expressed recombinant PPARc, clearly establish that in
opossum kidney cells ERK activity is a prerequisite for
efficient stimulation of PPRE, and that ERK inhibition
abolishes PPRE activation both under basal conditions
and when stimulated by PPARc ligands. Nonetheless, in
opossum kidney cells endogenous PPARc is clearly phos-
phorylated in response to ligand activation, more so by
15d-PGJ2 than by ciglitazone. The 15d-PGJ2–mediated
stimulation of PPARc phosphorylation may be mediated
by ERK because this agent itself stimulates ERK activ-
ity. It seems unlikely that the increased PPARc phos-
phorylation evoked by ciglitazone is ERK mediated,
however, because ERK is not stimulated under this con-
dition. Other kinases such as c-Jun N-terminal kinase
have been shown to phosphorylate PPARc [37] but fur-
ther identification of the kinase responsible is beyond the
scope of this study.
According to the system under study 15d-PGJ2 and thi-
azolidinediones have been shown to have varying effects
on ERK activity. In certain studies both PPARc ligands
stimulate ERK, whereas in some only one or the other
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Fig. 6. 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) but not cigliat-
zone activates extracellular signal-regulated protein kinase (ERK) in
opossum kidney cells. Opossum kidney cells were exposed to 5 lmol/L
15d-PGJ2, 5 lmol/L ciglitazone or media change and lysed after vari-
ous times. Lysates were subjected to immunoblotting for either pERK
(upper panel for each condition) or total ERK (lower panel for each
condition). Immunoblots shown are representative of at least three ex-
periments.
has this ability [29, 31, 38–40]. Emerging evidence impli-
cates PPARc-independent mechanisms in the activation
of ERK by these agents. However, in our study only 15d-
PGJ2 was able to activate ERK and for two reasons the
results suggest, although do not definitively prove, that
activation of ERK by 15d-PGJ2 is mediated directly via
PPARc. First, the activation kinetic for ERK by 15d-PGJ2
is relatively long and sustained, thus being compatible
with a transcription dependent event. Second, it is an-
tagonized by ciglitazone and troglitazone, two different
PPARc ligands.
A variety of effects of different PPARc ligands on cell
growth and proliferation have been described depending
on the ligand used and/or the cell type studied [41–43].
– + + + + 5 µmol 15d-PGJ2
– – 0.1 0.5 1 Thiazolidinedione µmol/L
Ciglitazone
Troglitazone
Fig. 7. Thiazolidinediones inhibit 15-deoxy-∆12,14-prostaglandin J2
(15d-PGJ2) stimulated extracellular signal-regulated protein kinase
(ERK) activity in opossum kidney cells. Lysates from opossum kidney
cells stimulated with both 15d-PGJ2 and increasing concentrations of
ciglitazone (upper pair of panels) or troglitazone (lower pair of panels)
were immunoblotted for pERK (top panel of each pair) or total ERK
(lower panel of each pair). Immunoblots are representative of three
identical experiments.
Such observations have stimulated considerable interest
in the roles of PPAR ligands in cancer and inflammation,
although few studies in kidney cells have been performed.
In our previous studies of human proximal tubular cells
both 15d-PGJ2 and fatty acid PPARc ligands stimulated
apoptosis of kidney cells, as did overexpression of PPARc
[13]. However, kidney cell responses to 15d-PGJ2 appear
to be context specific, varying with applied concentra-
tion and cell type studied. Rovin et al [44] found that at
low concentrations 15d-PGJ2 stimulated mesangial cell
proliferation, but at higher concentrations induced cell
death. Thiazolidinediones at low concentrations were less
potent stimulators of proliferation than 15d-PGJ2 but
at higher concentrations the ability of these agents to
induce apoptosis was similar. The results of our stud-
ies are similar in that 15d-PGJ2 stimulated robust pro-
liferation of proximal tubular cells at low concentra-
tion, whereas thiazolidinediones had an inhibitory effect
on cell proliferation. Furthermore, both ciglitazone and
troglitazone at low concentration were able to antagonize
the proproliferative effect of 15d-PGJ2. Our toxicity data
suggest that cell death would likely occur at higher doses
of these compounds, and that any proliferative responses
would be abolished. However, it was not our aim to study
this directly.
The current findings that thiazolidiendiones (1) fail
to elicit full PPRE activation; (2) inhibit 15d-PGJ2–
mediated PPRE activation; (3) block 15d-PGJ2–induced
PPARc phosphorylation; (4) prevent 15d-PGJ2 stimula-
tion of ERK; and (5) stop 15d-PGJ2–mediated prolifer-
ation indicate that in opossum kidney cells two differ-
ent thiazolidiendiones behave as partial PPARc agonists
compared to 15d-PGJ2. Other PPARc-binding thiazo-
lidinedione and nonthiazolidinedione compounds have
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Fig. 8. Proliferative responses of opossum kidney cells exposed to 15-
deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) and thiazolidinediones. (A)
Opossum kidney cells were exposed to increasing concentrations of ei-
ther 15d-PGJ2, ciglitazone, or troglitazone. Proliferation was measured
by [3H] thymidine incorporation and counts accumulating in nonstimu-
lated cells were arbitrarily assigned a value of 100%. (B) Opossum kid-
ney cells were stimulated with 5 lmol/L 15d-PGJ2 alone () or 5 lmol/L
15d-PGJ2 together with increasing concentrations of ciglitazone () or
troglitazone (). Proliferation was measured by [3H] thymidine incor-
poration and values are expressed as a percentage of those obtained
from nonstimulated cells. Values are expressed as means ± SEM. Each
condition was measured in triplicate in four experiments.
been shown to have partial agonist activity. Reginato
et al [45] described MCC-555, a thiazolidinedione with
context specific effects on PPARc transcriptional activ-
ity. Depending on the cell type studied this agent was
able to act as a full agonist, partial agonist, or antagonist.
Another compound, GW0072, binds PPARc with high
affinity but exhibits weak partial agonist activity with a
relative efficacy equal to ∼20% of rosiglitazone, while an-
tagonizing the effects of rosiglitazone itself [46]. Rosigli-
tazone activation of PPRE can also be blocked by the
nTZpa, a nonthiazolidinedione PPARc ligand [47]. Most
recently Misra et al [48] described a PPARc ligand thi-
azolidinedione, PAT5A, which interacts differently with
PPARc leading to differential cofactor recruitment and
thus gene activation compared to rosiglitazone.
To the best of the authors’ knowledge this is the first
study to demonstrate partial agonist effects of established
thiazolidinediones. The results of the current study indi-
cate a pharmacologic basis for the use of thiazolidine-
diones to combat progressive proteinuric renal disease,
such that a partial agonist thiazolidinedione may be em-
ployed to inhibit detrimental effects of other PPARc lig-
ands in proximal tubule and other kidney cells.
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